Oncology

Latest News

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a case study in small cell lung cancer (SCLC) illustrates.

Diabetes monitoring | Image credit: abidika - stock.adobe.com
New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com
Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

April 22nd 2025

Patient navigation | Image credit: AON
With Thyme Care Partnership, AON Achieves $6M in Savings in EOM’s First Performance Period

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
December 28th 2013

Presentation 3: Defining and Measuring Quality Outcomes in Oncology

Lee N. Newcomer, MD, MHA
Dr Newcomer says that he welcomes the transition of oncology from being evaluated in process measures to outcome measures. He says that while quality measures can be quick and messy, these results are used for the purpose of finding gaps and seeing if those gaps can be improved.
Site Logo
December 28th 2013

Discussion 2: Implications of Healthcare Reform: 'No†Will Be Heard

Cliff Goodman, PhD A. Mark Fendrick, MD John L. Fox, MD, MHA Ira M. Klein, MD, MBA, FACP
Implications of Healthcare Reform: 'No' Will Be Heard is led by Cliff Goodman, PhD, in a panel discussion featuring A. Mark Fendrick, MD, co-editor in chief of The American Journal of Managed Care, John L. Fox, MD, MHA, and Ira M. Klein, MD, MBA, FACP. The panelists determine what it means when a patient says no.
Site Logo
December 28th 2013

Presentation 2: Incorporating Patient-Centered Outcomes in Clinical Trials

Ethan Basch, MD
Ethan Basch, MD, a self-described triple-threat, discusses incorporating patient-centered outcomes into clinical trials. He begins his presentation by describing a colleague's published research article, Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. The study found that not only did Pazopanib cost an estimated $5800 and Sunitinib $7800, but Pazopanib was superior to Sunitiniib in 11 out of 14 quality-of-life indicators.
Site Logo
December 28th 2013

Presentation 1: Oncology Practice in the Era of PCMHs and ACOs: Square Pegs or Round Holes?

Peter B. Bach, MD, MAPP
Dr Peter Bach says professionals are looking at opportunities for new payment models and care redesign, but there are also threats that might surface. Each type of insurance payment model has different levels of risk factors. New payment models, such as the UHC pathways program and CMMI demo, have limited risk.
Site Logo
December 26th 2013

Value of Genetic Testing in Breast Cancer

Katie Sullivan
The value of genetic testing in breast cancer is subject to debate, but it also holds promise. One recent clinical trial simulated by a group of researchers, for instance, found that the 7 single-nucleotide polymorphisms (7SNP) genetic test for breast cancer was cost-effective when used for MRI screenings in patients at intermediate risk of developing the disease over their lifetime.
Site Logo
December 23rd 2013

Economics of Genomic Testing for Women With Breast Cancer

Robert D. Lieberthal, PhD
All the economic studies of genomic tests for breast cancer rely on modeling rather than randomized controlled trials or other direct trial data.
Site Logo
December 20th 2013

Outrage at the Increasingly High Cost of Cancer Drugs

Cancer drug prices have doubled in the past decade, from an average of $5,000 per month to more than $10,000.
Site Logo
December 13th 2013

The Quest for Better Survivorship: Guidelines Promote More Accountable Cancer Care

Peter Page
Site Logo
December 13th 2013

FDA Approves Ibrutinib for Mantle Cell Lymphoma

Silas Inman
Site Logo
December 13th 2013

Genetic Testing Should Come With Counseling: American Cancer Society CMO, Supreme Court Plaintiff Among Experts Who Warn of Consumer Risks

Nicole Beagin
Site Logo
December 13th 2013

Oncology Groups Active in Effort to Repeal SGR

Mary K. Caffrey
Site Logo
December 13th 2013

Current Thinking Behind Decision Making in Oncology Clinical Pathway Design

Rhonda Greenapple, MSPH
Treating the Signs of Multiple Myeloma Before it Starts
December 8th 2013

Treating the Signs of Multiple Myeloma Before it Starts

Progress in treating multiple myeloma, or cancer of the plasma cells in bone marrow, has advanced significantly over the past decade. Today, questions about the disease often involve finding a treatment that balances the goal of putting a patient into remission especially if stem cell transplantation is a possibility against the toxicity of the treatment itself.
Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than Ever
December 8th 2013

Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than Ever

With grants from government sources looking less certain, partnerships between academic research center and pharmaceutical companies are more important than ever to keep breakthrough hematology therapies in the pipeline, said Burt Adelman, MD, a hematologist who serves as executive vice president and chief medical officer for Dyax Inc.
In Treating Older CLL Patients, Cost Considerations Are a Factor
December 8th 2013

In Treating Older CLL Patients, Cost Considerations Are a Factor

New therapies to treat chronic lymphocytic leukemia (CLL) will receive plenty of attention this week at the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. At an education session that opened the meeting Saturday, a physician with the Mayo Clinic made it clear that cost considerations are a reality for many older patients.
Site Logo
November 27th 2013

Doctors Argue for Decision Aids to Promote Patient Engagement

Research on how tools impact health, costs is 'inconclusive,' but clinicians say better-informed patients avoid unnecessary care, frustration
Episode 13 - Final Insights
November 26th 2013

Episode 13 - Final Insights

Episode 12 - Specialty Pharmacy's Role in CRPC
November 26th 2013

Episode 12 - Specialty Pharmacy's Role in CRPC

Episode 11 - Personalized Medicine in CRPC
November 26th 2013

Episode 11 - Personalized Medicine in CRPC

Episode 10 - End-of-Life Care in CRPC
November 26th 2013

Episode 10 - End-of-Life Care in CRPC

Episode 9 - Benefit Design and Making Treatment Affordable
November 26th 2013

Episode 9 - Benefit Design and Making Treatment Affordable

Episode 8 - Impact of Payment Reform on Prostate Cancer Treatment
November 26th 2013

Episode 8 - Impact of Payment Reform on Prostate Cancer Treatment

Episode 6 - Treatment Response Rates in Step Therapy
November 26th 2013

Episode 6 - Treatment Response Rates in Step Therapy

Episode 7 - Treatment Coverage in Castration-Resistant Prostate Cancer
November 26th 2013

Episode 7 - Treatment Coverage in Castration-Resistant Prostate Cancer

Episode 5 - Pharmacoeconomic Considerations
November 26th 2013

Episode 5 - Pharmacoeconomic Considerations

Episode 4 - Treatment Guidelines and Economic Considerations
November 26th 2013

Episode 4 - Treatment Guidelines and Economic Considerations

Episode 3 - Radium-223 for the Treatment of CRPC
November 26th 2013

Episode 3 - Radium-223 for the Treatment of CRPC

Episode 2 - Immunotherapy in CRPC
November 26th 2013

Episode 2 - Immunotherapy in CRPC

Episode 1 - CRPC: Recent Advances and Paradigm Shifts in Treatment
November 26th 2013

Episode 1 - CRPC: Recent Advances and Paradigm Shifts in Treatment

Site Logo
November 18th 2013

More Than 200 Attend AJMC's Patient-Centered Oncology Care; Experts Discuss Cost of Treatment, 'Culture of Medicine'

More than 200 participants gathered in Baltimore for "Patient-Centered Oncology: Real-World Perspectives," which covered genetic testing, how to engage patients in decision-making, and how the "culture of medicine" continues to drive up costs despite calls to abandon the fee-for-service payment model.
<1
...
166167168169170171172173174
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo